Navigation Links
Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
Date:8/30/2010

talix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system.  Protalix's ProCellEx (TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.  Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease.  Protalix's new drug application (NDA) for taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
For more information on Protalix, visit http://www.protalix.com.

Safe Harbor StatementTo the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements, including statements relating to the perceived effects of dual listing on the market for our common stock, are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Factors that might cause material differences include, among others, risks relating to the trading of our common stock on the Tel Aviv Stock Exchange or the NYSE Amex, risks relating to our continued compliance with the rules of the Tel Aviv Stock Exchange and the NYSE Amex and other
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Protalix Announces Successful GMP Manufacturing Audit by Israels Ministry of Health
2. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
3. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
4. Northwest Biotherapeutics Secures $700,000 Equity Financing
5. Oxygen Biotherapeutics, Inc. Expands Board of Directors
6. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
7. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
8. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
11. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... ROCKVILLE, Md. , March 30, 2015 ... company dedicated to the acquisition, development and commercialization of ... for the global market with a commercial focus on ... China Food and Drug Administration (CFDA) has approved the ... trial in ovarian clear cell carcinoma (OCCC) patients for ...
(Date:3/30/2015)... 2015 Immunocore Limited, a ... treat cancer, viral infections and autoimmune disease, today ... Bell , the Regius Professor of Medicine at ... the Strategic Coordination of Health Research, to its ...      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ) , ...
(Date:3/29/2015)... 2015  Caris Life Sciences® today announced ... cell cervical cancer (SCCC) that shows multiplatform ... company,s panomic, comprehensive tumor profiling service, identified high ... explain sensitivities and resistance to common drug ... biomarkers may guide treatment strategies in rare, ...
(Date:3/27/2015)... 2015  Peter Walter wurde als Gewinner ... seine bahnbrechende Arbeit ausgewählt, die sich damit ... sowie für die Entschlüsselung der Komponenten eines ... nutzen, der mit der Ansammlung von deformierten ... Biochemie an der University of California, San ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... SEATTLE , June 2 Dendreon Corporation (Nasdaq: DNDN ... elected to the Company,s Board of Directors.  Dr. Stump is currently executive ... HGSI ), where he has been a member of its management ... , "We ...
... ... ... -- DuPont has entered into agreements to acquire AgVenture, Kentland, Ind.; Hoegemeyer Hybrids, ... business’ PROaccess℠ strategy. Closings are scheduled to occur in the latter part of 2010. ...
... , June 2 Repligen Corporation (Nasdaq: RGEN ) announced ... fiscal year 2010, on Wednesday, June 9th, 2010 , before the market ... Ph.D., will host a conference call and webcast on the same day at ... quarterly update on the Company. , , ...
Cached Biology Technology:Dendreon Announces Election of Dr. David C. Stump to Board of Directors 2Dendreon Announces Election of Dr. David C. Stump to Board of Directors 3DuPont Enhances its PROaccess℠ Business Strategy Through Acquisitions 2DuPont Enhances its PROaccess℠ Business Strategy Through Acquisitions 3DuPont Enhances its PROaccess℠ Business Strategy Through Acquisitions 4Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 3
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
(Date:3/23/2015)... 23, 2015 SoundView Technology Group issues a new ... NXTD ) Wocket smart wallet. SoundView was one of the selected ... experience with the Wocket in multiple scenarios and outlets. ... and other retailers, making both debit and credit card payments.  ... says, "If the company meets their plans in 2015, it ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... release is available in German . ... many animal species. During mating season male testosterone levels ... masculine features. Male bonobos, however, invest much more into ... would collide with this increased tendency towards forming pair-relationships. ...
... lot easier if there is a dog or cat around. ... managing their chronic illness, according to a new study from ... Reserve University. "We think this finding about pets can ... Webel, instructor of nursing and lead author of the article, ...
... University] For the 26 million Americans with diabetes, ... glucose levels. It is invasive and at least minimally ... new sensor that can check blood sugar levels by ... takes advantage of a convergence of nanotechnology and surface ...
Cached Biology News:Bonobos' unusual success story 2CWRU study finds the love of a dog or cat helps women cope with HIV/AIDS 2Biochip measures glucose in saliva, not blood 2Biochip measures glucose in saliva, not blood 3
Rab1A...
... LYZL6 ( Abpromise for all ... Synthetic peptide: DWLCL AFVE SKFNISKINE ... to amino acids 46-100 of Human ... ID: 57151 ...
Request Info...
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: